Xenon Pharmaceuticals Inc.
XENE
株式のランク
#4663
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
株価
$33.60
最終同期: 2026-10-16
時価総額
$3.25B
変化（1日）
-2.13%
変化（1年）
-19.29%
国
CA
取引 Xenon Pharmaceuticals Inc. (XENE)
カテゴリー
Healthcare
Xenon Pharmaceuticals Inc.（XENE）のEPS
June 2026 時点のEPS TTM: $-4.74
Xenon Pharmaceuticals Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-4.74です。2023年末には、EPSは$-2.73で、2022年のEPS$-2.06と増加でした。
Xenon Pharmaceuticals Inc.のEPS履歴（2011から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-4.74 | 57.48% |
| 2024 | $-3.01 | 10.26% |
| 2023 | $-2.73 | 32.52% |
| 2022 | $-2.06 | 16.38% |
| 2021 | $-1.77 | 113.25% |
| 2020 | $-0.83 | -46.10% |
| 2019 | $-1.54 | -13.48% |
| 2018 | $-1.78 | 4.09% |
| 2017 | $-1.71 | 15.54% |
| 2016 | $-1.48 | 34.55% |
| 2015 | $-1.10 | -217.02% |
| 2014 | $0.94 | 123.81% |
| 2013 | $0.42 | -113.00% |
| 2012 | $-3.23 | -64.19% |
| 2011 | $-9.02 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -465.40% |
US
|
|
| $-7.98 | 68.35% |
US
|
|
| $-5.29 | 11.60% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -685.23% |
NL
|
